Vagal Modulation of Hypertension

Current Hypertension Reports

Volumn 17, Issue 4, 2015, Pages

  Petkovich, Bradley W ^a   Vega, Joshua ^a   Thomas, Sabu ^a  

^a STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

Baroreflex activation; Renal denervation; Rheos; SYMPLICITY; Vagal

Indexed keywords

BLOOD PRESSURE REGULATION; CHOLINERGIC SYSTEM; DIASTOLIC BLOOD PRESSURE; HUMAN; KIDNEY DENERVATION; NONHUMAN; PRESSORECEPTOR REFLEX; RESISTANT HYPERTENSION; REVIEW; SENSORY NERVE; SYSTOLIC BLOOD PRESSURE; VAGUS NERVE STIMULATION; ANIMAL; BLOOD PRESSURE; HYPERTENSION; KIDNEY; PATHOPHYSIOLOGY; PHYSIOLOGY; SYMPATHECTOMY;

ANIMALS; BAROREFLEX; BLOOD PRESSURE; HUMANS; HYPERTENSION; KIDNEY; SYMPATHECTOMY; VAGUS NERVE STIMULATION;

EID: 84925358485     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-015-0532-6     Document Type: Review

References (24)

1. Schwartz PJ, Vanoli E, Stramba-Badiale M, De Ferrari GM, Billman GE, Foreman RD. Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. Circulation. 1988;78(4):969–79.
2. Mortara A, La Rovere MT, Pinna GD, Prpa A, Maestri R, Febo O, et al. Arterial baroreflex modulation of heart rate in chronic heart failure: clinical and hemodynamic correlates and prognostic implications. Circulation. 1997;96(10):3450–8.
3. Gibson TE. The present status of renal sympathectomy. Calif West Med. 1936;45(1):10–3.
4. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510–26.
5. Lohmeier TE, Irwin ED, Rossing MA, Serdar DJ, Kieval RS. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension. 2004;43(2):306–11.
6. Lohmeier TE, Dwyer TM, Hildebrandt DA, Irwin ED, Rossing MA, Serdar DJ, et al. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension. 2005;46(5):1194–200.
7. Lohmeier TE, Hildebrandt DA, Dwyer TM, Iliescu R, Irwin ED, Cates AW, et al. Prolonged activation of the baroreflex decreases arterial pressure even during chronic adrenergic blockade. Hypertension. 2009;53(5):833–8.
8. Schmidli J, Savolainen H, Eckstein F, Irwin E, Peters TK, Martin R, et al. Acute device-based blood pressure reduction: electrical activation of the carotid baroreflex in patients undergoing elective carotid surgery. Vascular. 2007;15(2):63–9.
9. Illig KA, Levy M, Sanchez L, Trachiotis GD, Shanley C, Irwin E, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg. 2006;44(6):1213–8.
10. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58(7):765–73.
11. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6(2):152–8. Following the completion of the Rheos Pivotal Trial, this longer term follow-up revealed that SBP/DBP reductions were able to be maintained at 22–53 months while also reducing the number of hypertension medications.
12. Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6(4):270–6.
13. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81.
14. Symplicity HTNI, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9.
15. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401. This is the first randomized controlled trial involving a sham group for renal sympathetic denervation which previously had revealed significant drops in blood pressure. This important study has created a great amount of controversy given the previous significant results without a sham group.
16. Patel HC, Hayward C, Di Mario C. SYMPLICITY HTN 3: the death knell for renal denervation in hypertension? Glob Cardiol Sci Pract. 2014;2014(1):94–8.
17. Hauptman PJ, Schwartz PJ, Gold MR, Borggrefe M, Van Veldhuisen DJ, Starling RC, et al. Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. American heart journal. 2012;163(6):954–62 e1.
18. De Ferrari GM, Tuinenburg AE, Ruble S, Brugada J, Klein H, Butter C, et al. Rationale and study design of the NEuroCardiac TherApy foR Heart Failure Study: NECTAR-HF. Eur J Heart Fail. 2014;16(6):692–9.
19. Sabbah HN. Electrical vagus nerve stimulation for the treatment of chronic heart failure. Cleve Clin J Med. 2011;78 Suppl 1:S24–9.
20. Handforth A, DeGiorgio CM, Schachter SC, Uthman BM, Naritoku DK, Tecoma ES, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology. 1998;51(1):48–55.
21. Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS. Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation. 2008;118(8):863–71.
22. Plachta DT, Gierthmuehlen M, Cota O, Espinosa N, Boeser F, Herrera TC, et al. Blood pressure control with selective vagal nerve stimulation and minimal side effects. J Neural Eng. 2014;11(3):036011. This study reveals new and upcoming methods to effectively stimulate selective vagal nerve efferents within a nerve bundle within rats that could potentially have benefits in future designs for vagal modulation of hypertension.
23. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046–58.
24. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150(9):1881–4.